Germany's Bayer to launch three new Xarelto trials

Germany's Bayer unveiled plans to launch three new studies to expand the uses of its anti-clotting drug Xarelto, one of its top five new medicines. Xarelto, which competes with the Eliquis pill developed by Bristol-Myers Squibb and Pfizer in stroke prevention, reached sales of $1.7 billion in the 12 months to June. Bayer said on Friday that a Phase III trial involving about 7,000 patients would examine whether Xarelto can help prevent the recurrence of strokes in patients who have suffered strokes of undetermined cause. "We really have just as many strokes due to undetermined causes as to atrial fibrillation," Frank Misselwitz, head of the Therapeutic Area Cardiovascular and Coagulation at Bayer HealthCare, told Reuters.



via Health News Headlines - Yahoo News http://ift.tt/1sQbToR